The definition of neuronopathic Gaucher disease

Raphael Schiffmann¹, Jeff Sevigny², Arndt Rolfs³, Elin Haf Davies⁴, Ozlem Goker-Alpan⁵, Magy Abdelwahab⁶, Ashok Vellodi⁷, Eugen Mengel⁸, Elena Lukina⁹, Han-Wook Yoo¹⁰, Tanya Collin-Histed¹¹, Aya Narita¹², Tama Dinur¹³, Shoshana Revel-Vilk¹³, David Arkadir¹⁴, Jeff Szer¹⁵, Michael Wajnrajch¹⁶, Uma Ramaswami¹⁷, Ellen Sidransky¹⁸, Aimee Donald¹⁹, Ari Zimran^{13

14}

Affiliations

¹ Baylor Scott & White Research Institute, Dallas, Texas.
² Prevail Therapeutics, New York, New York.
³ Centogene AG, Rostock, Germany.
⁴ Aparito, Ltd, Gwenfro Technology Park, Wrexham, UK.
⁵ Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), Fairfax, Virginia.
⁶ Department of Pediatric Hematology, Cairo University Pediatric Hospital, Cairo, Egypt.
⁷ Bushey Herts WD23 1DU, Bushey, UK.
⁸ Clinical Science for LSD, Hochheim, Germany.
⁹ National Research Center for Hematology, Moscow, Russia.
¹⁰ Asan Medical Center, Department of Pediatrics, Medical Genetics & Genomics Center, Seoul, South Korea.
¹¹ International Gaucher Alliance, Dursley, UK.
¹² Division of Child Neurology, Institute of Neurological Science, Tottori University Faculty of Medicine, Yonago, Tottori, Japan.
¹³ Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
¹⁴ Hebrew University-Hadassah Medical School, Jerusalem, Israel.
¹⁵ Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
¹⁶ Pfizer Inc., Clinical Professor of Pediatrics, New York University Langone School of Medicine, New York, New York.
¹⁷ Lysosomal Storage Disorder Unit, Royal Free Hospital, London, UK.
¹⁸ Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
¹⁹ University of Manchester, St Marys Hospital, Manchester, UK.

PMID: 32242941
PMCID: PMC7540563
DOI: 10.1002/jimd.12235

The definition of neuronopathic Gaucher disease

Raphael Schiffmann et al. J Inherit Metab Dis. 2020 Sep.

. 2020 Sep;43(5):1056-1059.

doi: 10.1002/jimd.12235. Epub 2020 Apr 3.

Authors

Affiliations

¹ Baylor Scott & White Research Institute, Dallas, Texas.
² Prevail Therapeutics, New York, New York.
³ Centogene AG, Rostock, Germany.
⁴ Aparito, Ltd, Gwenfro Technology Park, Wrexham, UK.
⁵ Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), Fairfax, Virginia.
⁶ Department of Pediatric Hematology, Cairo University Pediatric Hospital, Cairo, Egypt.
⁷ Bushey Herts WD23 1DU, Bushey, UK.
⁸ Clinical Science for LSD, Hochheim, Germany.
⁹ National Research Center for Hematology, Moscow, Russia.
¹⁰ Asan Medical Center, Department of Pediatrics, Medical Genetics & Genomics Center, Seoul, South Korea.
¹¹ International Gaucher Alliance, Dursley, UK.
¹² Division of Child Neurology, Institute of Neurological Science, Tottori University Faculty of Medicine, Yonago, Tottori, Japan.
¹³ Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
¹⁴ Hebrew University-Hadassah Medical School, Jerusalem, Israel.
¹⁵ Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
¹⁶ Pfizer Inc., Clinical Professor of Pediatrics, New York University Langone School of Medicine, New York, New York.
¹⁷ Lysosomal Storage Disorder Unit, Royal Free Hospital, London, UK.
¹⁸ Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
¹⁹ University of Manchester, St Marys Hospital, Manchester, UK.

PMID: 32242941
PMCID: PMC7540563
DOI: 10.1002/jimd.12235

Abstract

Neuronopathic Gaucher disease (nGD) has a very wide clinical and genotypic spectrum. However, there is no consensus definition of nGD, including no description of how best to diagnostically separate the acute form-Gaucher type 2-from the subacute or chronic form-Gaucher type 3. In this article, we define the various forms of Gaucher disease with particular emphasis on the presence of gaze palsy in all patients with nGD. This consensus definition will help in both clinical diagnosis and appropriate patient recruitment to upcoming clinical trials.

Keywords: Gaucher disease; diagnosis; gaze palsy; lysosomal disease.

PubMed Disclaimer

Conflict of interest statement

Dr Schiffmann received research support and honorarium from Sanofi Genzyme and Protalix Biotherapeutics.

References

1. Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease In: Beaudet AL, Vogelstein B, et al., eds. Valle D. New York: The Online Metabolic and Molecular Bases of Inherited Disease, McGraw‐Hill Medical; 2014.
1. Goker‐Alpan O, Schiffmann R, Park JK, Stubblefield BK, Tayebi N, Sidransky E. Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. J Pediatr. 2003;143:273‐276. - PubMed
1. Abdelwahab M, Blankenship D, Schiffmann R. Long‐term follow‐up and sudden unexpected death in Gaucher disease type 3 in Egypt. Neurol Genet. 2016;2:e55. - PMC - PubMed
1. Choy FY, Zhang W, Shi HP, et al. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles. Blood Cells Mol Dis. 2007;38:287‐293. - PubMed
1. Eto Y, Ida H. Clinical and molecular characteristics of Japanese Gaucher disease. Neurochem Res. 1999;24:207‐211. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The definition of neuronopathic Gaucher disease

Affiliations

The definition of neuronopathic Gaucher disease

Authors

Affiliations

Abstract

Conflict of interest statement

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical